Hui Sheng Biotech: Net profit of 206 million yuan in the first half of 2026, a year-on-year increase of 75.59%.

According to Huisheng Biotechnology's announcement, in the first half of 2026, the operating revenue reached 865 million yuan, an increase of 5.20% year-on-year. The net profit attributable to shareholders of the listed company was 206 million yuan, a year-on-year increase of 75.59%, compared to 117 million yuan for the same period in 2025. The net profit attributable to shareholders of the listed company, deducting non-recurring gains and losses, was 142 million yuan, an increase of 43.26% year-on-year. The company's profit distribution plan is as follows: based on the existing total share capital of 202 million shares, after excluding the repurchased shares of 1.3709 million shares, a cash dividend of 3 yuan will be distributed for every 10 shares to all shareholders, with 0 bonus shares being issued and no capital reserve being converted into additional shares.